|
⚲
|
| Keyboard |
| Farallon Capital Management LLC
✚
|
|
|---|---|
| CRD # | 107322 |
| SEC # | 801-51763 |
| CIK # | 0000909661 |
| AUM | 52.08 B (2026-03-30) |
| Employees | 355 (36% Investors, 0% Brokers) |
| Phone | 415-421-2132 |
| Address | One Maritime Plaza San Francisco, CA 94111 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Tue, 30 Jun 2026 | Farallon Capital Management LLC Increases Stake in Centessa Phar — GuruFocus |
| Wed, 24 Jun 2026 | Farallon Capital Management Discloses Investment in Centessa with 6.1% Stake — TradingView |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 1.3 | ||
| Amazon Com Inc | 0.9 | ||
| Microsoft Corp | 0.9 | ||
| Aon Corp | 0.8 | ||
| Bridgebio Pharma Inc | 0.7 | ||
| Protagonist Therapeutics Inc | 0.7 | ||
| Natera Inc | 0.6 | ||
| Exelixis Inc | 0.6 | ||
| Broadcom Inc | 0.6 | ||
| UnitedHealth Group Inc | 0.5 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Farallon Special Situations Master Fund III Non-US LP | [2024-06-10] | 964.6 M | |
| Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Situations Master Fund III US LP | [2024-06-10] | 217.4 M | |
| Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Situations Master X-VII LP | 2023-03-29 | 268.5 M | |
| HF | Farallon Co-Investment Master Fund LP | [2022-08-04] | 0.1 M | 49.8 M |
| Filed 2025-05-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Real Estate Institutional Partners IV LP | [2022-08-04] | 460.7 M | |
| Filed 2022-07-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Farallon Real Estate Partners IV LP | [2022-08-04] | 200.9 M | |
| Filed 2022-07-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Investment Institutional Partners IV LP | [2022-02-14] | 104.7 M | 100.0 M |
| Filed 2021-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Farallon Special Situations Master Credit IX LP | 2022-02-14 | 259.6 M | |
| HF | Farallon Healthcare Partners Master LP | [2021-08-03] | 510.5 M | 4,503.8 M |
| Filed 2025-07-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Capital F5 CC LP | 2021-03-30 | 295.4 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 66 | 52.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.1 |
| Total | 67 | 52.1 |
| By Discretionary | ||
| Discretionary | 67 | 52.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 67 | 52.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 21.9 | |
| United States Persons | 30.1 | |
| Total | 67 | 52.1 |
| Limited Partners | 2011 - 2026 |
|---|---|
| New Jersey Division of Investment | |
| Virginia Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Grant Jackson | Director | 175 | 39 | |
| Martin Lang | Director | 161 | 31 | |
| Russell Burt | Director | 113 | 29 | |
| David Kim | Executive Officer | 88 | 7 | |
| Michael Fisch | Executive Officer | 42 | 5 | |
| Michael Linn | Executive Officer | 41 | 4 | |
| Daniel Hirsch | Executive Officer | 29 | 3 | |
| Cameron Hillyer | Executive Officer | 27 | 3 | |
| Thomas Steyer | Executive Officer | 21 | 3 | |
| Jason Moment | Executive Officer | 13 | 3 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0000909661] | |
| 3 | [0000909661] | |
| 4 | [0000909661] | |
| SC 13D | [0000909661] | |
| SC 13G | [0000909661] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $28.9B |
| Clients | 1 (63 non-US) |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 87DR6WT2MK1KMGUC7161 |
| Related People Network |
|---|
| 47 people file Form D offerings alongside this firm's people. |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Generation Bio Co GBIO
Common Stock
|
2020-06-16 | Conversion | 1,518,819 | ||
|
Generation Bio Co GBIO
Common Stock
|
2020-06-16 | Buy | 400,000 | $19.00 | 7,600,000 |
|
Generation Bio Co GBIO
Series C Preferred Stock · derivative
|
2020-06-16 | Conversion | 2,682,691 | ||
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 249,462 | $6.72 | 1,676,385 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 833,845 | $6.72 | 5,603,438 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 915,583 | $6.72 | 6,152,718 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 899,268 | $6.72 | 6,043,081 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 209,577 | $6.72 | 1,408,357 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 2,067,651 | $6.72 | 13,894,615 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 122,006 | $6.72 | 819,880 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 2,648,696 | $6.72 | 17,799,237 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 3,007 | $3.36 | 10,104 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 3,303 | $3.36 | 11,098 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 9,554 | $3.36 | 32,101 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 440 | $3.36 | 1,478 |
|
Nexvet Biopharma PLC NVET
Ordinary Share
|
2016-02-26 | Buy | 3,244 | $3.36 | 10,900 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 756 | $3.36 | 2,540 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 7,458 | $3.36 | 25,059 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 900 | $3.36 | 3,024 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-25 | Buy | 65,694 | $3.18 | 208,907 |
| showing 20 of 163 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Marshall Wace North America LP
✚
|
NY | 58.87 B |
|
Blackstone Private Credit Strategies LLC
✚
|
NY | 57.92 B |
|
TA Associates Management LP
✚
|
MA | 55.07 B |
|
Veritas Capital Fund Management LLC
✚
|
NY | 53.81 B |
|
Blackstone Liquid Credit Advisors I LLC
✚
|
NY | 51.63 B |
|
Crescent Capital Group LP
✚
|
CA | 49.71 B |
|
ICG Investments Inc
✚
|
NY | 49.69 B |
|
Macquarie Infrastructure Partners Inc
✚
|
NY | 48.84 B |
|
Antares Capital Advisers LLC
✚
|
IL | 47.39 B |
|
Silver Point Capital LP
✚
|
CT | 46.23 B |